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Abstract
The epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine kinase family that plays a role in multiple
cellular processes. Activation of EGFR requires binding of a ligand on the extracellular domain to promote conformational
changes leading to dimerization and transphosphorylation of intracellular kinase domains. Seven ligands are known to bind
EGFR with affinities ranging from sub-nanomolar to near micromolar dissociation constants. In the case of EGFR, distinct
conformational states assumed upon binding a ligand is thought to be a determining factor in activation of a downstream
signaling network. Previous biochemical studies suggest the existence of both low affinity and high affinity EGFR ligands.
While these studies have identified functional effects of ligand binding, high-resolution structural data are lacking. To gain a
better understanding of the molecular basis of EGFR binding affinities, we docked each EGFR ligand to the putative active
state extracellular domain dimer and 25.0 ns molecular dynamics simulations were performed. MM-PBSA/GBSA are efficient
computational approaches to approximate free energies of protein-protein interactions and decompose the free energy at
the amino acid level. We applied these methods to the last 6.0 ns of each ligand-receptor simulation. MM-PBSA calculations
were able to successfully rank all seven of the EGFR ligands based on the two affinity classes: EGF.HB-EGF.TGF-
a.BTC.EPR.EPG.AR. Results from energy decomposition identified several interactions that are common among
binding ligands. These findings reveal that while several residues are conserved among the EGFR ligand family, no single set
of residues determines the affinity class. Instead we found heterogeneous sets of interactions that were driven primarily by
electrostatic and Van der Waals forces. These results not only illustrate the complexity of EGFR dynamics but also pave the
way for structure-based design of therapeutics targeting EGF ligands or the receptor itself.
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Introduction
Receptor tyrosine kinases (RTK) play essential roles in
numerous cellular processes. Activation of an RTK by a particular
ligand(s) enables transduction of a biological signal from the
membrane surface to intracellular signaling pathways [1]. Ligand
binding to the extracellular domain of an RTK promotes
dimerization, leading to auto-phosphorylation by the intracellular
kinase domain [2]. One subgroup of the RTK family, the ErbB or
Her family, includes the epidermal growth factor receptor (EGFR,
ErbB1, Her1). EGFR is necessary for cell proliferation and
survival. Misregulation of the ErbB family, either through ErbB
ligands or the receptors themselves, has been implicated in several
diseases including glioblastoma, breast, skin, and lung cancer [3].
As with all RTKs, activating ligands bind to the extracellular
domain of EGFR. The mechanism of ligand-dependent activation
of EGFR has been studied in great detail [4]. High-resolution
crystal structures of the extracellular domain of EGFR in the
ligand-bound and unbound states demonstrated that binding of
EGF promotes several large-scale conformational changes leading
to EGFR dimerization (Figure 1) [5,6]. These studies also showed
that EGFR ligand binding is bivalent. Two beta-solenoid domains
of EGFR clamp EGF in the ligand binding site, while two cysteine-
rich domains control auto-inhibition by burying the dimerization
interface in the absence of a ligand.
Seven different ligands are known to bind to EGFR: epidermal
growth factor (EGF), betacellulin (BTC), heparin-binding EGF-
like growth factor (HB-EGF), amphiregulin (AR), epiregulin
(EPR), transforming growth factor-a (TGF-a), and epigen (EPG)
[7]. They are synthesized as transmembrane proteins that are
cleaved to produce soluble growth factors. Each soluble EGFR
ligand shares a common fold termed the EGF-like motif. This fold
is characterized by a consensus sequence of spatially conversed
cysteine residues that form three disulfide bonds. Additionally,
HB-EGF and AR contain amino-terminal heparin binding
domains. Structural analysis of six of these ligands, with EPG
being the exception, illustrated a common globular structure [5,8–
10].
While much attention has been paid to the biochemical and
physiological roles of EGFR ligands, little is known about the
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e54136
protein-protein interactions that determine the binding affinity of a
given ErbB ligand. EGFR ligands generally fall into two classes:
high affinity or low affinity. High affinity ligands (EGF, TGF-a,
HB-EGF, and BTC) bind with a dissociation constant (Kd)
between 1 and 100 nM, while low affinity ligands (AR, EPR, and
EPG) show a Kd greater than 100 nM [11,12]. Ranking of these
ligands has been difficult as previous reports have used a variety of
binding conditions, receptor constructs, and cell lines. Some
studies have not controlled for heterodimerization of EGFR with
another ErbB ligand, or ligand binding to another ErbB receptor.
Beyond knowledge of the ranking of the seven ligands,
understanding the molecular determinants of EGFR ligand
binding may provide insight into the observations that differences
in cellular signaling by EGFR occur when cells are treated with
different agonists or different concentrations of the same ligand for
a particular ErbB receptor [13].
In this study we explore the interactions between the
extracellular domain of EGFR and its ligands in order to
understand the side chain and backbone interactions that give
rise to the experimentally observed binding affinities. While
biophysical analyses can provide information on intermolecular
interactions, molecular dynamics (MD) simulations provide atom-
by-atom resolution and dynamical behavior on a nanosecond
timescale. Previous modeling studies of EGFR have illustrated the
asymmetric nature of dimer formation and kinase function. Using
theoretical free energy methods combined with conventional MD
simulations, we sought to determine residue-residue interactions
that give rise to binding affinities for each EGFR ligand.
Results
Docking and molecular dynamics simulations of EGFR
ligands
To explore the differences in binding affinity of an EGFR ligand
to the receptor, we chose to use computational methods to dock
each ligand to the extracellular domain of EGFR (sEGFR) and
compute the relative free energies. Accurate free energy prediction
of protein-protein interactions is one of the long standing goals of
computational biology [14]. Due to high computational costs,
accuracy of force field parameters, and complexity of large
solvated systems, computational free energy studies can be time
consuming and may only yield approximate binding affinities.
With these limitations in mind, we chose to simulate the sEGFR
dimer bound to each ligand and compute only relative free energy
differences. This allows us to rank each ligand but prevents
determination of the absolute binding energy. Computation of
absolute binding energies comes with a high computational cost
for each system (.200 k atoms), a quasi-harmonic approximation
of entropy, and is further complicated by energetic contributions
from transmembrane and intracellular domain association in the
full length EGFR receptor.
The crystal structures for the sEGFR dimer structure bound to
two EGF molecules (PDB code: 1IVO) were used as a starting
model for the docking of each ligand. In this structure, electron
densities for the ligand binding domains (DI and DIII) and the
domain containing the dimerization arm (DII) were well resolved.
Domain IV, however, was more disordered and initially could not
be fit to the density maps. Therefore we chose to model the fourth
domain DIV using the inactivated structure of EGFR bound to
EGF (PDB code 1NQL) as a reference [15]. A structural
alignment of our model compared to the recently resolved x-ray
structure of EGF-EGFR (PDB code: 3NJP) revealed an overall
root mean squared deviation of 2.89 A˚ [16]. Another crystal
structure of an EGFR dimer has been previously determined
bound to TGF-a [5]. Both dimer structures illustrated similar
positions of the ligand in the binding pocket and similar
conformations of the first three domains (Figure S2). To dock
the other five known EGFR ligands, each ligand’s backbone was
aligned with position-conserved atoms in EGF (Figure 2). To
remove any steric overlap, we performed a 1000-step energy
minimization using the Amber force field parameters in the
molecular visualization program Chimera [17] (Table 1).
Figure 1. Structural model of ligand dependent activation of EGFR. a) Structure of EGF (blue) bound to domain I of the auto-inhibited
conformation of the extracellular domain. The two ligand binding domains are colored red, domain II green and domain IV grey. b) Upon ligand
binding EGFR coordinate the two ligand binding domains in a clamp like fashion and dimerization occurs.
doi:10.1371/journal.pone.0054136.g001
Computation Modeling of EGFR Ligand Binding
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e54136
To determine if each ligand causes different structural
alterations in the EGFR dimer, we compared conformations of
each ligand-protein complex at the end of the production
simulations to the TGF-a-EGFR and EGF-EGFR complexes. A
recent structural study of an ErbB4-neuregulin-1b complex
highlighted two different types of interactions between ligand-
ErbB complexes in vitro [18]. In this study the authors identified a
rotational motion about the dimerization arms that disrupts the
dimer contacts, giving rise to asymmetric dimers. They deter-
mined this by studying the orientations of the dimer interface for
known ErbB-ligand structures, particularly two coordinated loops
(EGFR residues 190–208). In the case of their ErbB4 structure and
that of EGF-EGFR, these loops are staggered with respect to each
other in the dimer interface while their positions are flush in the
TGF-a-EGFR structure (Figure S3). From these observations they
concluded that flush dimer interfaces were more stable than
staggered interfaces, giving rise to the observed negative
cooperativity in cell binding assays. Our simulations revealed
both staggered and flush interfaces (Figure 3). In the extreme case,
EPG was unable to adopt a flush conformation and the loops were
distorted by the rotation about domains I and III. This exposure
may partially explain low binding affinity and also agrees with the
PBSA/GBSA results discussed below. EGF and TGF-a induced
flush conformations while AR, BTC, HB-EGF, and EPR adopted
staggered conformations.
Ligand sequence and structural conversation
Each EGFR ligand shares a common EGF-like motif (or fold).
This fold is characterized by three intramolecular disulfide bonds
constraining three solvent-accessible loops [19]. In addition to the
conserved cysteines, several other residues are conserved: two
aromatic residues (tyrosine or phenylalanine) at positions 13 and
22 (numbering based on position in EGF sequence), a nonpolar
residue at position 15, polar residue at 16, glycine at 18 and 39,
tyrosine at position 37, and a conserved arginine at 41 (Figure 4).
Mutational studies of tyrosine 13 demonstrated that substitution
with the phenylalanine or leucine retains 75% binding affinity
relative to wild type while other mutations cause a reduction of
more than 90% in binding affinity [20]. In addition, AR and HB-
EGF also possess N-terminal heparin binding domains that are
known to help stabilize the EGFR dimer with heparin sulfate
[21,22]. An atomic structure of EPG, the last EGFR ligand to be
identified, had not been determined at the time of this study.
Therefore we used a homology model of EPG based on the
homologous ligand EPR (44% sequence homology) [23]. After
minimized EGFR-ligand structural models were obtained for all
seven ligands, each was subjected to a 25 ns molecular dynamics
simulation. Solvent accessible surface area (SASA) values are one
measure of system stability SASA plots of each ligand-receptor
system were used to tell if the system was stable and converged
during the 25 ns simulation (Figure S1). These results indicated
that each EGFR dimer-ligand system was stable after 5.0 ns of a
molecular dynamics simulation.
MMPBSA ranking of EGFR ligands
While molecular dynamics simulations can provide us with a
qualitative assessment of intramolecular interactions, knowledge of
the energetic contributions from individual atoms or residues can
Figure 2. Docking poses of EGFR ligands. Using the EGFR dimer
bound to EGF as a starting structure, the remaining six ligands were
docked to the binding pocket by alignment to the backbone of EGF
(Blue). AR is colored purple, BTC cyan, EPG brown, EPR green, HB-EGF
yellow and TGF-a orange.
doi:10.1371/journal.pone.0054136.g002
Table 1. Summary of structures used in MD simulations.
Ligand
Number of residues in
structure PDB code Method R.M.S.D. (A˚)* Binding affinity (Kd)
EGF 47 1IVO X-ray 0.00 0.6 nM
AR 50 2RNL NMR 1.45 350 nM
BTC 50 1IPO NMR 4.00 1.4 nM
EPR 46 1K37 NMR 1.90 2.8 mM***
HB-EGF 40 1XDT X-ray 0.93 7.1 nM
EPG 42 Q6UW88** Homology 2.05 .500 nM
TGF-a 50 1MOX X-ray 3.09 9.2 nM
*: Root mean square deviation relative to EGF in 1IVO structure,
**: SWISS-MODEL repository code for homology model database [41,42],
***: Murine Epiregulin.
doi:10.1371/journal.pone.0054136.t001
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provide a quantitative analysis of the binding mode of a ligand to a
protein. Molecular mechanics Poison-Boltzmann Surface Area
(MM-PBSA) calculations are a computationally efficient method to
compute relative binding affinities [24]. Enthalpy terms are
computed from the molecular mechanics energies recorded during
the simulation and the solvation of the receptor and ligand using
continuum solvent models coupled with salt models to account for
ionic solvent effects. Entropy is calculated using normal mode
analysis and can be is computationally expensive. It has been
shown that relative free energies omitting the entropy terms can be
used to calculated relative affinities and accurate ranking of ligands
[25]. MM-GBSA methods are more frequently used to predict
absolute binding energies because MM-PBSA depends more
heavily on the internal dielectric constant of the solute, which can
vary greatly depending on the system and the number of internal
ionizable groups [26]. Since the errors are dependent on sequence
content, ligands with homologous sequences would be expected to
have similar errors. This dielectric estimation error would not
affect PBSA when predicting accurate rankings, but could fail on
absolute binding energy predictions. Given the size of each EGFR
dimer-ligand complex, we chose to compute only relative binding
energies to see if MM-PBSA/GBSA could rank the EGFR ligands
based on the high and low affinity states. MM-PBSA results
(Table 2) ranked the ligands in the following order: EGF.HB-
EGF.TGF-a.BTC.EPR.EPG.AR. MMGBSA produced
different ranking results: EGF.TGF-a.HB-EGF.BTC.E-
PR.AR .EPG. (Table S1). Nonpolar solvation energies contrib-
uted favorably in all cases, as did electrostatic and van der Waals
forces. The polar contributions to EGFR binding, however, were
significantly unfavorable to binding in all complexes. This suggests
that the overall driving forces for EGFR ligand binding are
favorable van der Waals and electrostatic interactions, with little
contribution from nonpolar solvation energies.
Hydrogen bond and salt bridge analysis reveal
heterogeneous sets of interactions
Hydrogen bond lifetimes and salt bridges are indicators of stable
non-covalent interactions during the course of a MD simulation.
To investigate the interactions between EGFR and a given ligand
at the molecular level, we analyzed the last 6.0 ns of each
simulation using hydrogen bond and salt bridge analysis. We chose
to analyze only the last 6.0 ns as we want to ensure the stability of
each system. High occupancy hydrogen bonds were observed for
all ligands bound to EGFR (Figure 5). The results, summarized in
Table 3, suggest several conserved residues are involved in
hydrogen bonding and salt bridge formation. Our expectation was
that hydrogen bonding patterns, or lack thereof, would be similar
for both the high and low affinity ligand classes. A common set of
hydrogen bonds in all simulations occurred between glutamine 16
of EGFR and the backbone of the fourth and fifth conserved
cysteines of each ligand. Rather unexpectedly, high and low
affinity ligands did not share any additional hydrogen bonding
patterns. We did observe that the number of salt bridges (Table 4)
decreased in the lower affinity ligands. AR, EPG, and EPR formed
only two salt bridges during the 6.0 ns simulation window. This
suggests that the ability to form energetically favorable salt bridges
is a factor in EGFR ligand affinity.
Free energy decomposition of EGFR-ligand complexes
Binding hotspots on protein interfaces can dictate the experi-
mentally observed binding affinity. While alanine scanning
mutagenesis can provide some insight, it must be interpreted with
caution as exact knowledge of structural perturbations must be
considered [27]. Virtual mutagenesis or energy decomposition to
minimize the perturbation of the protein-ligand complex by
alanine substitution is an attractive alternative. To determine the
molecular interactions that give rise to the ranking of the EGFR
ligands, residue level decomposition analysis was performed to
identify sequence and structural motifs that may be affecting a
ligand’s binding affinity. To compare our GBSA/PBSA results
ranking results, we performed decomposition using both the GB/
PB models. We hypothesized that conserved residues in the EGFR
binding ligands may be necessary for high affinity binding in
addition to protein stability. We were also curious to see if the
differences between high and low affinity correlated with a subset
of position-specific amino acid residues that force EGFR in to a
certain conformational state.
The results of the residue decomposition analysis revealed
several amino acids that contribute to the overall binding energy
from the MM-PBSA/GBSA calculations (Figure 6). Six conversed
cysteines in each ligand are necessary for constraining three loops
that interact with the two ligand binding domains of EGFR. In
addition to providing structural stability, we found the fourth and
fifth cysteines contribute favorably to the overall binding energy by
0.00 to 3.76 kcal/mol. This observation agrees with the hydrogen
bond network formed by the backbones of the fourth and fifth
cysteines as well as glutamine 16 of EGFR. Another favorable
energetic contribution comes from a non-conserved residue
separating these two cysteine residues, providing 1.94 to
Figure 3. Alteration of the dimerization interface by ligand binding. Structural snapshots were taken at the end of the 25.0 ns production
runs. Top views generated by a 90 degree rotation about the x-axis of the structure provide a clear view of the dimerization loops (EGFR residues
190–208) thought to influence the overall strength of the an EGFR-ligand complex. Structures were generated for each ligand: a) AR, b) BTC, c) EGF, d)
EPG, e) EPR, f) HB-EGF and g) TGF-alpha.
doi:10.1371/journal.pone.0054136.g003
Figure 4. Sequence alignment of the EGFR ligands. a) Shown are the seven ligands used in the computational studies. Sequences of only the
EGF like domains of each ligand were used in the alignment. ‘‘*’’ represent 100% conservation while ‘‘.’’ and ‘‘:’’ represent partial sequence
conservation.
doi:10.1371/journal.pone.0054136.g004
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24.32 kcal/mol for six ligands. Several other conserved residues
were identified to contribute to binding: a conserved aromatic
residue at position 13 of EGF (20.09 to 22.34 kcal/mol), a
hydrophobic residue at position 15 (21.20 to 23.45 kcal/mol), a
non-conserved residue at position 28 (20.10 to 24.23), two
uncharged residues at positions 30(1.21 to 23.36 kcal/mol), and
Table 2. Free energy results from MM-PBSA.
Ligand DEele* DEvdw** DGPB*** DGSA**** DGMMPBSA
EGF 2176.5(8.30) 2148.12(10.48) 239.80(12.67) 217.42(0.88) 2102.29(5.56)
HB-EGF 2365.82(2.65) 2115.22(8.08) 402.20(13.29) 213.17(0.71) 292.30(2.09)
BTC 2425.56(66.03) 2115.78(6.69) 469.92(47.26) 213.49(0.87) 284.91(3.00)
TGF-a 2146.22(55.20) 2132.43(2.40) 217.96(42.92) 215.38(0.12) 286.08 (0.16)
AR 2207.08(0.87) 2100.29(1.13) 243.34(8.88) 212.20(0.43) 266.25(0.16)
EPR 2211.75(34.05) 2117.49(13.06) 265.01(31.06) 213.77(1.21) 277.99(12.92)
EPG 2121.95(13.23) 291.51(11.99) 150.58(12.80) 213.65(0.34) 276.14(12.17)
All units are given in kcal/mol. The standard state is taken to be 1 M.
*: DEele: coulombic energy.,
**:DEvdw : van der Waals energy.
***:DGPB: Poisson-Boltzmann polar solvation energy.
****:DGSA :non-polar solvation energy. Standard Errors of corresponding values are given in parentheses.
doi:10.1371/journal.pone.0054136.t002
Figure 5. Hydrogen bonding analysis of last 6.0 ns used for energy calculations. Snapshots of the EGFR domains I and III and EGFR protein-
protein interfaces from simulations were taken at a) 19.0 ns b) 21.0 ns c) 23.0 ns and d) 25.0 ns. Dotted lines represent hydrogen bonds that had
lifetimes of greater than 1.2 ns of the 6.0 ns time frame. The ligand binding domains are represented in red and EGF in blue.
doi:10.1371/journal.pone.0054136.g005
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38(0.48 to 24.50 kcal/mol and a conserved arginine at position
41. Previous mutational studies have shown the conserved arginine
41 (ARG41) is a requirement for EGF binding [28]. Mutation of
ARG41 to any other amino acid reduces binding affinity to less
than 1% of the wild type binding affinity. The energetic
contribution of the conserved ARG41 varied among ligands
(Figure 7). The GBSA values were all negative and ranged from
21.04 to 210.66 kcal/mol while the PBSA values varied from
2.59 to 26.24 kcal/mol.). Salt bridges between ASP355 on the
ligand binding domain II and ARG41 were not observed for HB-
EGF and BTC. In the case of BTC, the energetic contribution was
small (,21.03 kcal/mol). This is in contrast to HB-EGF where
arginine made a significant contribution (26.42 to 27.96 kcal/
mol). While no salt bridge was detected during the course of the
simulation for the conserved arginine in EPG, it did contribute
favorably to the overall DG in the GBSA calculations (21.21 kcal/
mol) but was unfavorable for the PBSA calculation (2.59 kcal/
mol). Position 32 (EGF: ASN32) also exhibited favorable energetic
contributions for all ligands. Position 32 is not conserved among
the members of the EGFR ligand, yet provides 22.28 to
24.32 kcal/mol for all seven EGFR ligands. While several
conserved interactions contributed variable amounts of energy to
the overall binding, one non-conserved position predicted to have
a large impact on the binding energy similar to the contribution
made by the ARG41. This position is located after the six
conserved cysteine and had variable effects for each ligand and
solvation method: favorable for BTC in both PBSA and GBSA
calculations, favorable for EGF with GBSA (,21.0 kcal/mol) and
PBSA results and ,21.0 kcal/mol for PBSA/GBSA with AR.
Both PBSA and GBSA contributions for TGF-a were unfavorable
while both were favorable in the case of HB-EGF. Favorable
GBSA vales for EPG and EPR occurred in this position while
PBSA energies were unfavorable for the two. The range is +6.0 to
27.01 kcal/mol and appears to have a dominant effect on the
ranking. These results suggest that while some conserved residues
may be necessary for binding, non-conserved residues in
structurally similar positions may also provide a significant
contribution to the overall binding constant. It also appears that
reduction of interaction energy for conserved residues affects
binding affinities of the EGFR ligand family.
Table 3. Residues involved in hydrogen bonding during the last 6.0 ns of each simulation.
EGFR
residue EGF AR BTC TGF-a HB-EGF EPR EPG
SER11 TYR44
ASN12 GLY39 GLY44 GLY34
LYS13 GLU40 GLU45 GLU35 GLU36
LEU14 THR35 CYS32 CYS32 SER25
THR15 GLU40, CYS31 GLU45 GLU35,CYS26 GLU39
GLN16 CYS33, CYS31,ASN32 CYS38,CYS36, LYS26 CYS32,
CYS34
CYS32,CYS34 CYS28, CYS26,LYS16 CYS32, TYR29,CYS30, CYS27,
CYS29,
ARG28
LEU17 GLY40
GLY18 CYS29
ASP22 GLN40
SER26 GLU36
ARG29 ASP46 GLU36
TR45 CYS32
GLU90 LYS28 LYS29 LYS24
SER99 ALA25 HIS30 THR29 SER3 GLU20 ASP24
TYR101 HIS30 GLU20
ARG125 GLU27 GLU27
SER127 GLU27 GLU27
ASN128 GLU20
VAL350 GLU44 GLU42 GLU39
ARG353 ILE21 GLU44 GLU44 GLU39
ASP355 ARG41 ARG46 ARG42 ARG36 ARG40
SER356 ASN18 ASP8 TYR13 ASP6
GLN384 LYS50 GLY40 HIS12 PHE43, GLU42 LEU41
GLN408 LEU40
HIS409 ARG45
SER418 TYR50 ALA46 LEU46
LYS443 TYR50
SER468 GLU51,TRP50
ARG470 TYR50 ALA50
doi:10.1371/journal.pone.0054136.t003
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Discussion
Protein-protein interactions drive biological processes [29,30].
Ligand binding can turn on cellular signaling pathways and
modulate their amplitude and duration [31]. In the case of EGFR,
seven ligands are capable of binding the receptor resulting in
divergent biological responses. All mature EGFR ligands share a
common structure with multiple conserved residues involved in
binding [11]. Binding affinities for these ligands span three orders
of magnitude yet are still able to drive receptor activation in a
similar manner. While the physiological and cellular effects of
ligand binding have been studied extensively, the atomistic
determinants that give rise to binding affinity for an EGFR ligand
are still poorly understood. In this study we chose to explore these
molecular interactions using molecular dynamics simulations and
free energy post processing methods.
EGFR forms multiple intramolecular interactions with a ligand
by binding in a clamp-like fashion on domains I and III [5,6].
Ligand coordination is necessary for dimerization and stabilization
of the complex. Following ligand binding, intracellular kinase and
juxtamembrane domains undergo substantial conformational
rearrangements, promoting phosphorylation of the C-terminal
tail leading to recruitment of scaffold proteins [32]. Structural
studies have greatly enhanced our knowledge of EGFR activation
but have not been able to capture structural snapshots of binding
of all EGFR ligands or a structure of the full-length receptor [33].
To address this gap in our knowledge of ligand-dependent
activation of EGFR, we chose to perform molecular dynamics
simulations of the dimeric state of the extracellular domain bound
to each ligand. To characterize the effects of ligand binding on the
conformations of the EGFR dimers, we compared structures
generated during simulation runs to previously solved x-ray
structures of EGFR bound to TGF-a and EGF, and the recently
solved structure of another ErbB4-ligand complex [5,6,18]. The
structure of a Drosophila homolog of EGFR bound to the EGF-
homolog Spitz has also been determined [34].The overall
conformations of the EGFR-ligand complexes show asymmetrical
dimers in the presence of all seven ligands. We also observed
asymmetrical dimer formation for all of our simulations, suggest-
ing that human EGFR uses a similar mechanism as Drosophila
EGFR, but those properties cannot be captured with static
structures. [18] argues that distortion of the dimerization domain
by ligand binding can not only affect the stability of the complex
but also provides one possible explanation for the negative
cooperativity observed in cell binding assays. The authors from
this study claim that the solved structure of ErbB4 explains the
lower binding affinity by confirmation of loops found in the
dimerization interface. These loops are staggered in the ErbB4
complex and the EGF-EGFR x-ray structure but flush in the
TGF-a, possibly to the interactions of domain IV. We found
similar loop conformations in our simulations. Interestingly, EPG
loops showed extreme staggering, suggesting the ligand distorts
domains I and III. EPG is also a low affinity EGFR ligand. Some
of the higher affinity ligands were able to form nearly flush loop
conformations in the presence of domain IV in the dimer model.
This leads us to a similar conclusion that [18] made: that the
degree of domain II distortion may play a role in dimer stability
and possibly affect the binding affinity. We do recognize, however,
that we are only modeling the extracellular portion of the receptor
and these conformations could be changed when adding the
transmembrane and intracellular domains of EGFR.
Theoretical free energy methods allow prediction of both
relative and absolute binding energies from molecular dynamics
simulations [35–37]. The MM-PBSA/GBSA methods are efficient
ways to predict binding energies for large protein-ligand and
protein-protein complexes [38–40]. Ideally one would calculate
the enthalplic and entropic contributions of a protein-ligand
complex to compare with experimental binding assays. Unfortu-
nately entropic calculations using quasi-harmonic methods are
only approximate and can be computationally expensive. Forgoing
inclusion of entropic terms in the binding analysis prevents
determination of a total DG but does allow for ranking of ligands
using the relative MM-PBSA/GBSA free energies. This was
necessary for us as 600 frames of each EGFR-ligand simulation
system were used for DG post-processing and contained over
200,000 atoms including solvent water molecules.
Our MM-PBSA/GBSA results provided a ranking of ligands
that is close to the rankings according to previously determined
binding constants [3,16]. The PBSA results (EGF.HB-
EGF.TGF-a.BTC.EPR.EPG.AR) were able to accurately
rank the ligands with the exception of EPR. The original Kd value
measured for EPR was done using the mouse homolog which
contains several mutations in loop 2 and a mutation in loop 3 that
have negative PBSA/GBSA decomposition energies. This could
explain why the original binding affinity constant is significantly
lower than our predicted binding energy. Overall, hydrophobic
interactions along with electrostatic and van der Waals interac-
tions were the energetic driving forces for binding of all seven
ligands. The binding modes were similar in all cases; domains I
and III formed multiple hydrogen bond networks and salt bridges
with each ligand. Analysis of hydrogen bond lifetimes showed that
several hydrogen bonds formed, but specific networks were not
conserved across all ligands (Table 3 and Figure 5). The only
hydrogen bonds formed in all cases was between the backbone of
the fourth and fifth conserved cysteines and glutamine 16 of
domain I. Another residue, serine 99 in domain I, was able to form
hydrogen bonds with different residues on each ligand, with the
exception of EPG. Another strong interaction between receptors
and ligands that can be determined using simulation methods is
salt bridge formation. For the case of EGFR, lysine 13 on domain
I formed salt bridges with glutamates proximal to the conserved
arginine. This glutamate is partially conserved among 4 ligands
(EGF, AR, HB-EGF, and EPG). This partially conserved residue is
replaced with hydrophobic residues in BTC, TGF- a, and EPR.
Table 4. Salt bridges formed during 6.0 ns of each
simulation.
Salt Bridges
EGFR
residue EGF AR BTC TGF-a HB-EGF EPR EPG
LYS13 GLU39 GLU45 GLU90 GLU35 GLU36
ASP355 ARG41 ARG46 LYS13,
ARG42
ARG42 ARG40
ARG29 ASP46 GLU36
ARG353 GLU44 GLU44 ASP8 GLU39
ASP22 LYS48
ARG125 GLU27 GLU27
SER418
LYS443 GLU51
ASP102 ARG22 ARG22,
HIS4
GLU90 LYS28 ARG22
doi:10.1371/journal.pone.0054136.t004
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TGF-a, however, is able to form a salt bridge with a glutamate
occurring two positions after the arginine. Another salt bridge that
may be affecting the binding affinity occurs between the conserved
arginine and aspartate 355 on domain III of EGFR. This
interaction is conserved in all high affinity binding ligands and
also in EPR.
The PBSA results provide a roughly accurate ranking of the
ligands, but do not explain the low binding energy we calculated
for TGF-a. One possible explanation for this is that non-linear
solvation models may overestimate the binding energy of charged
atomic species. To further explore the relationship between the
non-covalent interactions found in each EGFR-ligand system and
an energetic contribution to the binding energy, we used energy
decomposition analysis with the MM-PBSA/GBSA methods. The
advantage of using decomposition analysis is it allows for
electrostatic contribution to the binding energy to be determined
at the amino acid residue level. This information can shed some
light on the atomic determinants of binding by determining the
energetic contribution for each residue in the protein and the
ligand. We found several conserved residues contribute favorably
to the overall binding energy. The PBSA decomposition of Glu44
in TGF-a showed this residue was contributed a significant
energetic penalty to binding (4.98 kcal/mol) (Figure S4). Further
analysis of the other six ligands revealed the PBSA energies for this
position either contributed unfavorably or zero value to the overall
binding energy. The GBSA results predicted zero or slightly
negative values for six of the seven ligands. GBSA results for Glu44
of TGF-a also predicted unfavorable free energy contribution but
with a value of less than 2.0 kcal/mol. The negative values
predicted for this position by GBSA appear to balance out the
energy values for the conserved arginine. If more favorable GBSA
energy values were predicted for this Glu44 position a given
ligand, the magnitude of the arginine contribution was decreased.
This charge-energy compensation effect was not repeatable with
PBSA energy predictions.
In summary, we have performed molecular dynamics simula-
tions of EGFR bound to each of its endogenous ligands. This study
provides for the first time, to our knowledge, a detailed view of
Figure 6. Comparison of decomposition energy values of GBSA and PBSA results. Graphs were generated using the numbering of EGF
residues for a) PBSA and b) GBSA results. The trace for EGF is colored blue, AR is colored purple, BTC cyan, EPG brown, EPR green, HB-EGF yellow and
TGF-a orange.
doi:10.1371/journal.pone.0054136.g006
Figure 7. A Conserved arginine in loop 3 is important for EGFR ligand binding a) Arg41 forms a salt bridge in the EGF-EGFR x-ray
structures (PDB IDs 1IVO and 3NJP) with Asp355. The energy decomposition values for Arg41 vary for each ligand. GBSA values are depicted
as solid black bars and PBSA values as shaded gray bars.
doi:10.1371/journal.pone.0054136.g007
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binding of all known EGFR ligands. We observed a similar
binding mode during the course of our simulations and our MM-
PBSA relative free energies were in agreement with previous
experimental data. GBSA results produced similar results but
failed to accurately rank EPR. We acknowledge that our studies
were done on only the extracellular domain and that the absence
of intracellular domains may affect our binding energies due to
conformational restraints. The accurate ranking of all seven
ligands suggests that binding is not affected by the intracellular
domains, though cooperative effects observed in full length
receptors cannot be ignored. Using residue level energy decom-
position analysis, we found several conserved and non-conserved
residues that the contributed to the overall binding energy. We
identified several conserved residues that contribute favorably to
the binding energy. We were also able to identify residues that
were position conserved in the structure of each ligand that
contributed to our predicted binding energies. The knowledge of
both sequence and structural information in regards to binding
may be applied to development of therapies targeting over-
expression of a particular set of EGFR ligands.
Materials and Methods
Structure preparation
Seven systems were constructed to model the binding of the
extracellular domain of EGFR to its endogenous ligands. The
initial extracellular dimer crystal structure bound to two EGF
molecules (PDB id 1IVO) was used [6]. In this structure only the
first three domains of EGFR were resolved; the fourth domain was
not initially fit to the electron density maps. We chose to model
domain IV to capture the structural features of the entire
extracellular domain. To do this we used the monomeric EGFR
extracellular domain bound to EGF (PDB ID 1NQL) which
contains domain IV and aligned domain III with domain III with
the EGFR-EGF complex. We then fused the domain IV to the C-
terminal chain of the dimer structure. Recently [16] re-refined the
initial x-ray data and was able to successfully fit domain IV to the
density maps (PDB id 3NJP). Our model showed an overall similar
conformation to this structure with a root mean squared deviation
of 2.89 angstroms.
X-ray structures have been solved for complexes with only two
EGFR ligands bound: EGFR and TGF-a. Three ligand structures
have been solved using NMR (AR, BTC, and EPR) and one x-ray
bound to the diphtheria toxin (HB-EGF; see table 1). The
structure of EPG, the last discovered of the EGFR ligands, remains
unsolved. In the absence of EPG structural data, we used a
previously determined homology model of EPG from the SWISS
repository [41,42]. The EPG model was predicted using the
GROMOS96 force field and was subject to 200 cycles of steepest
descent energy minimization followed by 300 cycles of conjugate
gradient minimization. Each ligand structure was then docked to
the EGFR dimer by alignment to the EGF molecule. To remove
steric overlap, we used the energy minimization function in the
UCSF Chimera visualization software [17]. Rigid body docking
procedures can lead to errors depending on the type of docking
search performed. Since we chose to manually dock our ligands,
we checked one complex against available structural data. One
such structure is that of TGF- a bound to an EGFR dimer. After
MD optimization of our initial docking, we performed cluster
analysis and compared the binding poses of the highest 10
populated states to the x-ray structure of TGF- a bound to EGFR.
The binding domains of EGFR adopted a similar confirmation to
the x-ray structure and the backbone of TGF- a was in a similar
position with respect to its bound confirmation in the x-ray
structure. Structural representations were visualized in Pymol [43].
Molecular dynamics
All simulations and system equilibrations were performed using
Amber 11 software. The leap module of AMBER11 was used to
create parameter and topology files for the MD simulations using
the AMBERff03.r1 force field [44]. Hydrogen atoms were added
and ionizable residues were set to predicted protonation states at
pH 7.0. Na+ counterions were added to each system to achieve
neutrality. TIP3 water molecules were added with a minimum
spacing of 10.0 A˚ from the box edges to the protein molecule.
Each system contained .200 k atoms. Energy minimization on
each system was performed in a two-step process. First the protein
atoms were restrained and the water molecules were allowed to
relax over 1000 steps. The entire system was then subjected to
energy minimization using the steepest descent method for the first
1000 steps, followed by the full conjugate gradient method for an
additional 2400 steps. Each system was then heated to 300 K for
100 ps followed by a 50 ps constant pressure simulation to adjust
the density to 1 g/mL. An additional 500 ps simulation was run
prior to production simulations to allow for further temperature
and pressure equilibration. Production runs were performed using
a canonical ensemble (NVT) scheme. Langevin dynamics with a
collision frequency of 2.0 were used for temperature regulation,
the SHAKE algorithm was used for all hydrogen atoms, and the
particle mesh Ewald (PME) method was employed to treat long-
range electrostatics and van der Waals forces (cutoff of 8 A˚) with
an integration step of 2.0 fs. All Amber equilibration and
production runs were performed using dual precision. All
production simulations were repeated in triplicate and extended
to 25.0 ns. Visualization of trajectories was performed in VMD
[45].
MMPBSA/MMGBSA Calculations
The binding energies between EGFR and each ligand were
calculated using the MM-PBSA/MM-GBSA method in Amber11
[46,47]. The MMPBSA method calculates a binding free energy
by the free energies of solvation for the complex (DGcomplex),
protein (DGprotein) and ligand (DGligand):
DGbind~DGcomplex{DGprotein{DGligand
Each term is calculated by determining the enthalpic energy of the
solute using molecular mechanics (EMM), the polar solvation free
energy (DGsolv), the nonpolar solvation free energy (DGnp) and the
entropic contribution (DS):
DG~SEMMTzSDGsolvTzSDGnpT{TSDST
The enthalpic term is taken as the average over the molecular
mechanics force field terms for the solute. The solute vibrational
entropy is estimated using either normal mode analysis or quasi-
harmonic approximation. DGsolv is solved using the Poisson
Boltzmann (PB) equation. The nonpolar term DGnp is solved using
the Generalized Born (GB) method and is assumed to be
proportional to the SASA [48]:
DGnp~cSASAzb
Where c is the surface tension, set to 0.0072 kcal/A˚2. b is an offset
value used to correct for the nonpolar contribution to the solvation
free energy term and is dependent on the GB model used [49].
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For each EGFR-ligand system, MM-PBSA and MM-GBSA
calculations were performed using 600 snapshots over the last
6.0 ns of the simulation with 100 ps intervals. All energy values,
including decomposition values, represent at least two indepen-
dent MD simulation runs for each ligand-protein complex. All
calculations were performed with the MMPBSA.py.MPI module
in Amber 11 with an ionic strength equal to 0.1 M. For MM-
PBSA calculations the PB equation is solved numerically by the
PBSA program included with AmberTools. The hydrophobic
contribution is approximated by the LCPO method implemented
within sander [50]. For MM-GBSA calculations the Hawkins,
Cramer, Truhlar pairwise GB model was used with parameters
described by Tsui and Case [51].
Binding free energy decomposition
To determine the energetic contribution of an individual residue
to DG, in silico alanine mutagenesis is usually performed, yielding a
DDGala. A major drawback to this method is that mutations in
macromolecular structures may cause perturbations that transcend
the binding interface [24]. To circumvent this problem a GB
model can be implemented to calculate the electrostatic contribu-
tion to DGsolv [52,53]. The GB model is defined as:
EGBpol~{
1
2
1{
e{kfGB
ev
 X
i,j
qiqj
fGB
Where qi and qj are atomic partial charges, k is the Debye-Huckel
screening parameter and ev is the solvent dielectric constant,
which is set to 80.0 for water. fGB is defined as:
fGB~ r
2
i,jzaiaje
{r2
i,j
4aiaj
 2
64
3
75
1=2
Where ri,j is the distance between the ith and jth atom, ai and aj
are the effective Born radii.
The ith atom contribution to the electrostatic free energy is
obtained by solving:
Eielec~{
1
2
X
j
1{
e{kfGB
ev
 
qiqj
f GBi,j (ri,j)
z
1
2
X
i=j
qiqj
ri,j
For each EGFR-ligand system the energy decomposition analysis
was done using the GB and PB solvation models. The analysis was
performed on the ligand and the receptor using 600 snapshots over
the last 6.0 ns of the simulation with 100 ps intervals.
Hydrogen bond and salt bridge analysis
Hydrogen bonding analysis was performed in the Hydrogen
Bond module of VMD [45]. We used a distance cut off of 3.2 A˚
and a maximum angle of 30 degrees between the donor and
acceptor heavy atoms. Using the last 6 ns of each simulation, we
recorded any unique hydrogen bonds with a lifetime of $10% of
the simulation window. The Salt Bridges program in VMD was
used to determine any salt bridges between EGFR and a given
ligand. For this method we used an oxygen-nitrogen distance
cutoff of 3.4 A˚ [45].
Supporting Information
Figure S1 SASA fluctuations for each EGFR-ligand
complex. The trace for EGF is colored blue, AR is colored
purple, BTC cyan, EPG brown, EPR green, HB-EGF yellow and
TGF-a orange.
(TIF)
Figure S2 Modeling domain IV for EGFR dimers. a-b)
The x-ray structure of the EGF-EGFR dimer containing the first
three domains of EGFR(colored blue) and the monomeric EGFR-
EGF complex(colored magenta) containing domains I–IV were
aligned using domain III as a reference.
(TIF)
Figure S3 Dimerization domain interface of EGFR-
ligand structures. A) Structural alignment of EGFR-EGF
model (colored cyan) and TGF-a-EGFR x-ray structure (colored
magenta) (PDB ID 1MOX) complexes. B) Top down view of the
dimerization domains.
(TIF)
Figure S4 Decomposition values for position for 43.
GBSA values are depicted as solid black bars and PBSA values as
shaded gray bars.
(TIF)
Table S1 Free energy results for MM-GBSA calculations
of last 6.0 ns of each ligand-protein complex.
(DOC)
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